ArticleRheumatology international2025
Diagnostic and prognostic utility of complete blood count-derived ratios in giant cell arteritis: a retrospective fast-track clinic cohort study.
Article in Rheumatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early diagnosis and treatment of giant cell arteritis (GCA) can prevent complications like vision loss. Traditional inflammatory markers C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) lack specificity. Complete blood count (CBC) components (neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR)) are emerging biomarkers in autoimmune diseases, but their role in GCA remains unclear. To evaluate the clinical utility of CBC components in GCA diagnosis and prognosis. This retrospective study analyzed patients from the University of Washington's GCA fast-track clinic (2017-2024). Biomarkers were assessed using ROC curves, Kaplan-Meier survival analysis, and Cox proportional hazards models. Predictive models were developed using LASSO, stepwise, and Firth's penalized logistic regression, with data split into training and test sets. A total of 250 patients were included (119 GCA, 131 non-GCA). All CBC biomarkers were significantly associated with ESR and CRP, but correlation coefficients remained low, with the strongest correlation observed between monocytes and ESR (R = 0.55). CBC components showed moderate predictive ability for GCA diagnosis, vascular ultrasound (vUS) and temporal artery biopsy positivity, and mortality (area under the curve (AUC) range 0.5-0.694). Stepwise models integrating both CBC and inflammatory markers provided marginal improvements in predictive performance, with most models including one of each or, in some cases, NLR alone. A total of 23 patients died, with 13 deaths (10.9%) in the GCA group during a median follow-up of 2.45 years (1.17-42.25). In survival analyses, ESR and CRP lost significance after time-stratified adjustments, while PLR (hazard ratio (HR): 1.004, p = 0.018), NLR (HR: 1.082, p = 0.040), and MLR (HR: 3.655, p = 0.044) remained associated with mortality. The best mortality prediction model (AUC = 0.914) identified coronary artery disease, age at vUS, and time since first Rheumatology visit as key predictors. Diagnostic models reached an AUC of 0.920 based on vascular ultrasound, clinical suspicion, and American College of Rheumatology/European League Against Rheumatism classification, outperforming models based solely on inflammatory traditional inflammatory biomarkers or CBC parameters. Routine CBC-derived ratios showed independent associations with mortality and performed comparably to ESR and CRP for GCA diagnosis. Their integration into clinical models may offer a simple, low-cost strategy to support diagnostic and prognostic assessment, including in patients with normal inflammatory markers.
Indexed as
Identifiers
41269356What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.